Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 08 2025 - 4:30PM
Business Wire
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
dedicated to restoring protein expression by harnessing the body’s
potential with RNA medicine, today announced that management will
present at the 43rd Annual J.P. Morgan Healthcare Conference on
Wednesday, January 15, 2025, at 6:00 p.m. ET (3:00 p.m. PT).
A live audio webcast of the presentation will be available on
the Investors & News section of Stoke’s website at
https://investor.stoketherapeutics.com/ and can be accessed by
following this Link. A replay of the webcast will be available for
30 days following the presentation.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company
dedicated to restoring protein expression by harnessing the body’s
potential with RNA medicine. Using Stoke’s proprietary TANGO
(Targeted Augmentation of Nuclear Gene Output) approach, Stoke is
developing antisense oligonucleotides (ASOs) to selectively restore
protein levels. Stoke’s first compound, zorevunersen (STK-001), is
in clinical testing for the treatment of Dravet syndrome, a severe
and progressive genetic epilepsy. Dravet syndrome is one of many
diseases caused by a haploinsufficiency, in which a loss of ~50% of
normal protein levels leads to disease. Stoke is pursuing the
development of STK-002 for the treatment of autosomal dominant
optic atrophy (ADOA), the most common inherited optic nerve
disorder. Stoke’s initial focus is haploinsufficiencies and
diseases of the central nervous system and the eye, although proof
of concept has been demonstrated in other organs, tissues, and
systems, supporting its belief in the broad potential for its
proprietary approach. Stoke is headquartered in Bedford,
Massachusetts with offices in Cambridge, Massachusetts. For more
information, visit https://www.stoketherapeutics.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250108980972/en/
Stoke Media & Investor Contacts: Dawn Kalmar Chief
Communications Officer dkalmar@stoketherapeutics.com
781-383-8417
Doug Snow Director, Communications & Investor Relations
IR@stoketherapeutics.com 508-642-6485
Stoke Therapeutics (NASDAQ:STOK)
Historical Stock Chart
From Dec 2024 to Jan 2025
Stoke Therapeutics (NASDAQ:STOK)
Historical Stock Chart
From Jan 2024 to Jan 2025